Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Given Consensus Recommendation of “Buy” by Analysts

Shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) have earned a consensus recommendation of “Buy” from the thirteen analysts that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, ten have given a buy rating and two have assigned a strong buy rating to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $39.80.

CNTA has been the subject of several research reports. Wolfe Research started coverage on shares of Centessa Pharmaceuticals in a report on Tuesday, February 24th. They set an “outperform” rating and a $40.00 price objective for the company. Truist Financial raised their target price on shares of Centessa Pharmaceuticals from $33.00 to $38.00 and gave the stock a “buy” rating in a report on Thursday, January 29th. Piper Sandler reaffirmed an “overweight” rating on shares of Centessa Pharmaceuticals in a research report on Friday, January 16th. TD Cowen reiterated a “buy” rating on shares of Centessa Pharmaceuticals in a research note on Wednesday, January 14th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a report on Wednesday, January 21st.

Insider Buying and Selling at Centessa Pharmaceuticals

In other Centessa Pharmaceuticals news, insider Iqbal J. Hussain sold 38,951 shares of the business’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $25.15, for a total transaction of $979,617.65. Following the completion of the sale, the insider directly owned 57,645 shares in the company, valued at $1,449,771.75. The trade was a 40.32% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Karen M. Anderson sold 120,029 shares of the company’s stock in a transaction dated Friday, March 13th. The shares were sold at an average price of $26.25, for a total transaction of $3,150,761.25. Following the sale, the insider directly owned 62,085 shares of the company’s stock, valued at $1,629,731.25. The trade was a 65.91% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 307,997 shares of company stock valued at $8,192,203. 7.09% of the stock is owned by company insiders.

Institutional Trading of Centessa Pharmaceuticals

Large investors have recently added to or reduced their stakes in the business. TD Waterhouse Canada Inc. purchased a new stake in Centessa Pharmaceuticals during the fourth quarter valued at approximately $25,000. Caitong International Asset Management Co. Ltd purchased a new position in shares of Centessa Pharmaceuticals during the 4th quarter worth $36,000. T. Rowe Price Investment Management Inc. boosted its stake in shares of Centessa Pharmaceuticals by 7,580.0% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,536 shares of the company’s stock worth $39,000 after acquiring an additional 1,516 shares during the last quarter. Wells Fargo & Company MN grew its position in shares of Centessa Pharmaceuticals by 42.4% during the 4th quarter. Wells Fargo & Company MN now owns 3,387 shares of the company’s stock valued at $85,000 after acquiring an additional 1,008 shares during the period. Finally, Knott David M Jr bought a new stake in shares of Centessa Pharmaceuticals during the 4th quarter valued at $100,000. 82.01% of the stock is currently owned by institutional investors.

Centessa Pharmaceuticals Price Performance

CNTA opened at $27.06 on Monday. The company’s 50-day simple moving average is $25.26 and its two-hundred day simple moving average is $24.75. The company has a debt-to-equity ratio of 0.36, a quick ratio of 10.57 and a current ratio of 10.56. The stock has a market capitalization of $3.95 billion, a P/E ratio of -14.79 and a beta of 1.54. Centessa Pharmaceuticals has a 52-week low of $9.60 and a 52-week high of $30.58.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.